Abstract:
Eravacycline (TP-434) is a novel and fully synthetic, broad spectrum IV/oral antibiotic for treatment of complicated urinary tract infections and complicated intra-abdominal infections caused by multi-drug resistant Gram-negative and Gram-positive bacteria, anaerobic and atypical pathogens. Eravacycline is active against strains expressing all major mechanisms of antibiotic resistance to bacterial protein translation inhibitors, including tetracycline-specific efflux and ribosomal protection mechanisms. Furthermore, it is demonstrated greater potency in comparison to currently marketed antibiotics in clinical trials. It has recently gained qualified infectious disease product designation from FDA in 2013 for the treatment of complicated Intra-abdominal infection and complicated urinary tract infection.
